Although recent outcome data show that disease resistance has practically disappeared in almost all patients with genetically proven PML/RARA APL, CR being achieved with current therapies, there are still reports of rare cases with molecular persistence of disease at the end of consolidation that require immediate additional treatment, including HSCT if feasible [16]. This evidence concerns the gene PML and acute promyelocytic leukemia.